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Background: Preterm birth is a major cause of neonatal mortality, responsible for 28% of neonatal deaths overall.
The administration of antenatal corticosteroids to women at high risk of preterm birth is a powerful perinatal
intervention to reduce neonatal mortality in resource rich environments. The effect of antenatal steroids to reduce
mortality and morbidity among preterm infants in hospital settings in developed countries with high utilization is
well established, yet they are not routinely used in developing countries. The impact of increasing antenatal steroid
use in hospital or community settings with low utilization rates and high infant mortality among premature infants
due to lack of specialized services has not been well researched. There is currently no clear evidence about the
safety of antenatal corticosteroid use for community-level births.
Methods: We hypothesize that a multi country, two-arm, parallel cluster randomized controlled trial to evaluate
whether a multifaceted intervention to increase the use of antenatal corticosteroids, including components to
improve the identification of pregnancies at high risk of preterm birth and providing and facilitating the
appropriate use of steroids, will reduce neonatal mortality at 28 days of life in preterm newborns, compared with
the standard delivery of care in selected populations of six countries. 102 clusters in Argentina, Guatemala, Kenya,
India, Pakistan, and Zambia will be randomized, and around 60,000 women and newborns will be enrolled. Kits
containing vials of dexamethasone, syringes, gloves, and instructions for administration will be distributed.
Improving the identification of women at high risk of preterm birth will be done by (1) diffusing recommendations
for antenatal corticosteroids use to health providers, (2) training health providers on identification of women at
high risk of preterm birth, (3) providing reminders to health providers on the use of the kits, and (4) using a
color-coded tape to measure uterine height to estimate gestational age in women with unknown gestational age.
In both intervention and control clusters, health providers will be trained in essential newborn care for low birth
weight babies. The primary outcome is neonatal mortality at 28 days of life in preterm infants.
Trial registration: ClinicalTrials.gov. Identifier: NCT01084096
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One of the United Nations Millennium Summit goals is a
two-thirds reduction, by 2015, in death among children
under 5 years old [1]. Given that 38% of all under-5 deaths
worldwide occur in the first 4 weeks of life, the goal seems
unattainable unless a significant fraction of the neonatal
deaths are prevented [2]. Thus, the provision of perinatal
health care in developing countries is a top priority. Pre-
term birth is a major cause of neonatal mortality, currently
responsible for 28% of the deaths overall and is the second
most common cause of death of children under 5 years
old [2].
Interventions to reduce neonatal mortality: antenatal
corticosteroids
The most effective perinatal intervention to reduce neo-
natal mortality is the administration of antenatal corticos-
teroids to pregnant women at high risk of preterm birth
[3]. A high-quality systematic review including 18 trials
[4] found a 34% relative reduction in the incidence
of Respiratory Distress Syndrome (RDS) (risk ratio [RR]
0.66, 95% confidence interval [CI] 0.59–0.73), a 46% rela-
tive reduction in intraventricular hemorrhage (RR 0.54,
95% CI 0.43–0.69), and a 31% relative reduction in neo-
natal mortality (RR 0.69, 95% CI 0.58–0.81). These benefits
were confirmed irrespective of infant gender or race. The
trials conducted in specific subpopulations in developing
countries (preeclamptic women, or women with Premature
Preterm Rupture of Membranes (PPROM)) in Brazil,
Jordan, South Africa, and Tunisia, showed similar results
with estimates of the effect within the same 95% CIs [5].
There is no evidence of short-term adverse effects of
antenatal corticosteroids for the infants. In the subpopula-
tion of PPROM infants, there is no evidence of an
increased risk of infection (RR 1.05, 95% CI 0.66–1.68) [6].
There also has been no evidence of increased risk of
serious adverse events in mothers who received corticos-
teroids [3]. The risk of maternal infection was a concern,
specifically in women with PPROM, but a systematic re-
view conducted by Harding et al. examined 15 trials with
more than 1,400 women with PPROM and found no
increased risk of infection (RR 0.86, 95% CI 0.61–1.20) [6].
Maternal pulmonary edema can occur when antenatal cor-
ticosteroids are used in combination with tocolytic agents.
This complication is relatively rare and more commonly
associated with maternal infection, fluid overload, and mul-
tiple gestations. Pulmonary edema has not been reported
when antenatal corticosteroids are used alone.
To date, the trials of maternal corticosteroids have
been conducted in hospital settings. There is a need to
verify that the safety of corticosteroids would be similar
for births occurring at home or in community health
centers and where referral systems or advanced care for
preterm births are limited.Use in low-middle income countries
One indicator of the coverage of this intervention is the
proportion of preterm babies whose mothers received
the antenatal corticosteroids in a defined place and
period. Even in high-income countries, a proportion of
women at risk of preterm delivery do not receive
antenatal corticosteroids because of lost opportunities
or advanced labor, yielding an assumption of 80%
maximum rates of the intervention for preterm deliv-
eries below 34 weeks of gestational age (GA) [2,7,8].
In contrast, in 2000 in the 42 countries with 90% of
the worldwide childhood deaths, only about 5% of
mothers of preterm newborns received antenatal cor-
ticosteroids [9]. Another study based on data from
75 countries estimated that 10% of appropriate can-
didates received corticosteroids [2]. In Latin America,
six studies conducted between 1999 and 2009
reported that the use of antenatal corticosteroids in
preterm babies ranged between 4% and 71% [10-15].
Factors and causes of underuse
Why, despite the evidence of the past 30 years, are ante-
natal corticosteroids still not used routinely in low-middle
income countries? There is a need for studies to address
the contextual factors that affect the delivery of antenatal
corticosteroids and the achievement of high and equitable
coverage. The evidence supporting the use of antenatal
corticosteroids comes from trials that were conducted in
health facilities with neonatal intensive care units. There-
fore, there is no clear evidence that the same benefits
would be found in settings in which preterm babies could
not receive appropriate care, such as primary health
care centers or home births. It is likely that some of the
following factors are associated with the lack of use: (1)
Lack of availability of the drug; (2) Lack of guidelines
and local regulations about who can administer injec-
tions (In the Global Network settings, Traditional Birth
Attendants (TBAs), who are not allowed to administer
injections, attend 40% of the deliveries); (3) Health pro-
viders’ lack of knowledge about of the beneficial effects of
antenatal corticosteroids and misconceptions that corticos-
teroids produce adverse effects; (4) Difficulty identifying
women at high risk of preterm birth in these settings; (5)
Lack of accessibility to an appropriate level of care. At the
hospital level in low-middle income countries, the major
causes of underuse are the lack of availability of the drug
and the lack of an active strategy to promote its use.
Rationale for the trial
The effect of antenatal corticosteroids to reduce mortality
and morbidity among preterm infants delivered in
hospital settings in high-income countries is well-
established [4]. However, the impact of increasing
antenatal steroid use in hospital or community
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been well researched. Similarly, the safety of corticos-
teroids is well proven in women delivering at the
hospital level; however, there is currently no clear
evidence about the safety of antenatal corticosteroid
use for community-level births.
This is a pragmatic cluster, randomized controlled trial
designed to evaluate the effects of a multifaceted interven-
tion that will improve the identification of pregnancies at
high risk of preterm birth and will provide and facilitate
the appropriate use of corticosteroids to women at risk of
preterm delivery, with the goal of reducing neonatal mor-
tality rates among preterm infants in communities with
low antenatal corticosteroid use. The intervention will tar-
get the health system as whole, not individual patients.
Our hypothesis is that the multifaceted intervention will
improve the identification and referral of pregnant women
at high risk of preterm birth, increase the availability of
antenatal corticosteroids and facilitate their appropriate use
in eligible women and thus reduce neonatal mortality at
28 days in preterm newborns by 25%. We also hypothesize
that the therapy will be safe for women and their newborns.
Dexamethasone phosphate is the drug of choice for this
study because it is readily available in the participating
countries. This drug is used as the standard of care at the
hospital level for women at risk of preterm birth at many
of the sites. The primary objective will be to evaluate
whether a cluster-level multifaceted intervention, including
components to improve the identification of pregnancies at
high risk of preterm birth and to provide and facilitate the
appropriate use of corticosteroids, reduces neonatal mortal-
ity at 28 days of life in preterm newborns, compared with
the standard delivery of care. The secondary objective is to
determine whether the intervention is safe for women and
their newborns.
Methods/design
The study design is a two-arm, parallel cluster, rando-
mized controlled trial. Clusters will be randomized 1:1 to
an intervention group or to a control group. Specifically,
the intervention consists of the following: (1) training
birth attendants to identify risk factors for preterm birth
and to determine eligibility for antenatal corticosteroids
(2) using a color-coded tape to measure uterine height to
improve the assessment of gestational age (GA), and (3)
distributing kits with vials of corticosteroids and unique
reuse prevention syringes to all birth attendants for use in
the community. Neonatal mortality at 28 days will be
measured for all low birth weight (LBW) infants in control
and intervention clusters for a period of 18 months. LBW
will be used as a proxy for preterm birth because in Global
Network sites approximately 15% of the women who
delivered at health centers or homes did not know their
last menstrual period LMP dates, and 40% of the deliveriesoccurred at the community level, where ultrasound is not
available (Figure 1).Participating clusters
The Global Network for Women’s and Children’s Health
Research (GN) is comprised of seven geographical study
sites, located in low- and middle-income countries, which
function as research units for the various maternal and
neonatal studies implemented by the network. Each site
has research clusters, with 6 clusters in Argentina, 10 clus-
ters in Zambia, 10 clusters in Guatemala, 20 clusters in
Belgaum, India, 20 clusters in Nagpur, India, 20 clusters in
Pakistan and 16 clusters in Kenya. Seven GN sites will par-
ticipate in the ACT study and 102 clusters will be available
for the implementation of this protocol. The sizes of the
clusters differ across and within the GN sites, but each
cluster was selected because it had 300 to 500 deliveries
per year per cluster. The GN clusters include both rural
and urban settings, with deliveries taking place at home
and in health facilities. At this time, 40% of deliveries in
the participating clusters occur in home or clinic settings
with TBAs.
This is an intent-to-treat design and thus all pregnancy
outcomes of women who deliver in the study clusters and
provide consent will be collected. Cluster-level inclusion
criteria include GN clusters with at least 250 deliveries per
year that consent to participate. Participant-level inclusion
criteria include all pregnant women living in and delivering
in the study cluster, and identified as having high risk for
preterm birth who are eligible to receive intramuscular
corticosteroids and, in settings where it is not the standard
of care, provide consent.Randomization procedures
Data from the Maternal and Neonatal Health Registry
(MNH) - a prospective, population-based study of preg-
nancy outcomes at the seven GN sites - will be used as a
baseline to select the clusters and to ensure that the
underlying neonatal mortality rates are reasonably
balanced across arms through the randomization pro-
cedure [16]. The 102 clusters will be allocated to the
control or intervention groups. Because the GN sites
differ substantially, simple random allocation may
not provide adequate balance in the groups [17]. To
address this problem, we will implement a stratified
randomization procedure with strata defined based on
GN site, participation arm in a previous GN trial, the
Emergency Obstetric and Neonatal Care trial [18], and
neonatal mortality rate. The number and size of the
clusters, as well as the balanced randomization proced-
ure will make a clinically important imbalance in rele-
vant prognostic factors unlikely.
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General outline
The study intervention will be (1) to provide antenatal
corticosteroids kits (ready-to-use boxes containing cor-
ticosteroid vials, syringes, gloves, and instructions for ad-Figure 1 Trial Design. Design of the cluster randomized controlled trial to
survival in developing countries.ministration) (2) to improve the identification and referral
of women at high risk of preterm birth by training birth
attendants to identify eligible women, (3) to post eligibility
reminders at health facilities and in the boxes, (4) to meas-
ure uterine height with a color-coded tape to estimate GAincrease the use of antenatal corticosteroids to improve neonatal
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tration of antenatal corticosteroids to eligible women by
training birth attendants on its administration and en-
couraging its use through reminders at all primary health
care levels and at all health care levels in which women at
high risk of preterm birth could be attended.
Provision of antenatal corticosteroid kits
The study will distribute ready-to-use treatment kits con-
taining a full course of antenatal corticosteroids (4 vials
with 6-mg of dexamethasone phosphate), 4 reuse preven-
tion syringes, 4 pairs of gloves, and detailed instructions
on when, how, and to whom to administer antenatal corti-
costeroids (Figure 2).
The kits will be distributed in all health care facilities
and delivery settings where eligible women might attend.
Once an eligible pregnant woman is identified and has
already given her consent, the birth attendant will ad-
minister the first dose of corticosteroids intramuscularly.
The remaining 3 doses of dexamethasone will be admi-
nistered at 12-hour intervals, if the delivery has not oc-
curred, by either the same or another birth attendant.
After administration of the first dose, the remaining vials
will remain with the pregnant woman, along with a re-
minder for a health provider to administer the remaining
doses, in case the woman is referred to another level of
care or a different attendant is with her after 12 hours.
At the community level, the kits will be stored at the
primary health center with the health providers or
brought by the birth attendants when attending a home
birth to ensure that eligible women have access to the
medication. TBAs will be trained to identify pregnant
women at high risk of preterm delivery and a communica-
tion strategy will be put in place so that a qualified health
care provider is promptly informed of the situation.
All pregnant women who are between 24 weeks and
36 weeks GA will be eligible to receive antenatal corti-
costeroids if they present with any of the following: signs
of labor, or threatened labor, amniotic fluid leakage,
hemorrhage, or hypertension/severe headache.
Reminders to health care providers
Reminders in poster format will be placed in areas of care
(Figure 3). They include recommendations emphasizing
the importance of providing antenatal corticosteroids to
eligible women and why and whom to treat. Contents and
design were developed during the preparatory phase, in-
cluding translation to local languages and tailoring to the
characteristics of the different participating sites.
Improving the identification of eligible women
Treatment (antenatal corticosteroid injection) and refer-
ral will be recommended for all pregnant women who
are between 24 and 36 weeks GA and present with any ofthe following [19]: Signs of labor, or threatened labor
(intermittent abdominal pain, pain associated with
blood-stained mucus discharge, watery vaginal discharge
or a sudden gush of water, or any combination of these),
amniotic fluid leakage (watery vaginal discharge or a sud-
den gush of water), hemorrhage (vaginal bleeding with or
without cramping), hypertension (diastolic blood pressure
of 90 mmHg or more on two consecutive readings taken
at least 4 hours apart or 110 mmHg or more on one
reading). In communities where blood pressure cannot
be measured, women with eclampsia or signs or
imminent eclampsia (e.g. severe headache) will be offered
corticosteroids.
In some of the study communities, it is expected that an
estimation of GA in women with signs of labor or preg-
nancy complications will not be available. Preliminary data
from a previous GN study suggest that misclassification of
preterm deliveries is significant [20]. Additionally, data
from the GN sites suggest that approximately 15% of
women giving birth at the community level do not know
the date of their LMP.
As part of the development of the intervention, we
conducted a study to test a color-coded tape that we
developed to identify preterm pregnancies between 24
and 36 weeks GA through fundal height measurement.
Uterine fundal height measured by the color-coded tape
will be used as a proxy for GA when reliable GA assess-
ment is not available (Figure 4). The tape can be used in
all pregnant women presenting with any of the risk fac-
tors and an unknown GA. The tape is divided in two
segments, each shaded a different color; one segment
clearly indicates the uterine height corresponding to the
24–36 weeks GA range. If LMP or estimated date of de-
livery is known, GA will be assessed using a specially
designed obstetric disk (Figure 5). The use of the tape
and obstetric disk will not be promoted for women with
an ultrasound report verifying GA.
Intervention training
All the health providers potentially involved in delivery
attendance at intervention clusters will be trained to de-
liver the intervention during an interactive train-the-
trainer workshop. Workshop participants will learn how
to (1) identify those women eligible for antenatal corticos-
teroids administration and (2) appropriately use the pre-
term kit, if legally allowed to administer injections, and (3)
refer the woman to a health center or contact a skilled
birth attendant when indicated. We will adapt the work-
shops’ format according to the targeted health providers.
All birth attendants working in the intervention clus-
ters are eligible for participation in the trial if they pro-
vide care to pregnant women, assist in the delivery of
babies, and assist the women in caring for their babies.
We anticipate that approximately 3,000 birth attendants
Figure 2 Preterm Kit. Ready-to-use treatment kits containing a full course of antenatal corticosteroids (4 vials with 6-mg of dexamethasone), 4
reuse prevention syringes, 4 pairs of gloves, and detailed instructions on when, how, and to whom to administer antenatal corticosteroids
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briefed on the study before training and will be asked to
sign a Decline Form if they are not willing to receive the
training.
Post-randomization components
Both the intervention and control communities will receive
training in Essential Newborn Care for LBW Babies [20].
The purpose of this component is to ensure that all health
care providers at study sites that attend the mother or baby
are trained to use or promote the use of a minimum set of
evidence- based interventions for the care of LBW and
preterm infants born at homes or health care centers. The
selected interventions are (1) neonatal resuscitation, (2)
thermal regulation through skin-to-skin contact with the
mother, (3) breastfeeding, and (4) referral if needed.
Outcome measures
The primary outcome measure is neonatal mortality at
28 days of life in preterm infants in all clusters. LBWwill be used as a proxy for preterm birth because in GN
sites approximately 15% of the women who delivered at
health centers or homes did not know their LMP dates,
and 40% of the deliveries occurred at the community level,
where ultrasound is not available. Thus, pragmatically, it is
not possible to use gestational age to classify preterm births
in these settings.
The variable to be used for classifying preterm births
needs to be objective and unbiased in both intervention
and control clusters. Thus it should be unrelated to the ex-
perimental intervention. The color-coded tape (Figure 4) is
part of the intervention and will be used to improve the
identification of pregnancies at high risk of preterm birth,
but only in the intervention group. Therefore it is expected
that this group will show more reliable gestational age as-
sessment during the intervention period. Consequently,
using gestational age to select the preterm group will likely
introduce selection bias in the analysis.
Birth weight can be measured equally in both interven-
tion and control clusters, and it is unrelated to the
Figure 3 Poster Reminder. Poster to be placed in areas of care, including recommendations emphasizing the importance of providing
antenatal corticosteroids to eligible women and why and whom to treat
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ters is currently being done with high coverage (90%) and
good quality. It is likely that some misclassification with
small-for-gestational age (SGA) babies will exist, and that
this misclassification can underestimate the real benefit of
corticosteroids. But it is a conservative approach that will
not introduce bias to the comparison between groups.
GN sites have different mean birth weights; those from
Asian sites are much lower than those from African andLatin American sites. Using the same birth weight (e.g., <
2500 g) as a cutoff point at all sites would include a higher
proportion of Asian babies, whose mean birth weights are
~2700 g, and most of them would be SGA babies rather
than preterm. To avoid this, we will use different cutoff
points for each country to select the 10% smallest babies
in each GN site. Using data from the MNH study for each
GN site, we set a birth weight cutoff point, rounded to
100 g, that would select the smallest 10% of infants as a
Figure 4 Color-codedz tape. Both sides of the tape to measure uterine height and estimate gestational age in women with unknown
gestational age. Women with uterine height on the red zone are eligible to receive antenatal corticosteroids
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the cutoff point for sites in Argentina, Zambia, and
Kenya was 2500 g; for sites in Guatemala and Karnataka,
India, was 2400 g; and for sites in Nagpur, India, and
Pakistan was 2200 g. The overall prevalence of LBW for
all sites according to those weight limits is 8.2%, with
an 11.4% neonatal mortality at 7 days. A birth weight of
750 g will be used as a cutoff point for the lower birth
weight limit for analysis purposes, except for those GN
sites where babies with birth weights < 1000 g are con-
sidered abortions.
The primary and secondary outcomes in LBW babies,
the outcomes in all infants and their mothers, and the
process outcomes (to be measured only in the intervention
clusters) are shown in Table 1. LBW babies are definedFigure 5 Obstetric Disk. Disk to assess gestational age and facilitate the d
zone are eligible to receive antenatal corticosteroidsas newborns with birthweight below the 10th percentile of
the site.
Data collection and management
Outcome data for the ACT trial will be collected
through the existing MNH registry in the GN sites. This
registry includes all the outcome variables including data
to 42 days postpartum. Forms specific for ACT were
developed to collect process outcomes.
A weekly data transmission from the research units to
the Data Center will be completed using the system and
transmission procedures currently in place for GN studies
at each site. The data entry software will be programmed
to conduct range checks and simple consistency checks of
the data. Double data entry verification will be used toetection of eligible women. Women with gestational age in the red
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0.3% is considered acceptable.
The Data Management System is password protected. It
will require a user ID and password to be entered to
ensure that only trained, authorized personnel have access
to the data.Data analysis
The primary analysis will compare post-intervention out-
comes between intervention and control clusters, control-
ling for country, using two complementary approaches.
First, a cluster-based permutation test that is appropriate
for the stratified randomization process be used to de-
velop a formal hypothesis test and interval estimates of
the treatment difference between the two arms. A model-
based analysis will be used to assess whether the infer-
ences generated by the permutation test are robust
enough to control for potential confounders and to de-
scribe any evidence of differential treatment effects in the
different countries. Although this study is not powered to
evaluate treatment by country interactions formally, anyTable 1 Study outcomes
Outcome measures in infants with birth weight below 10th
percentile and their mothers
Outcome measures in all infants and their mothers
Process measuresevidence of such interactions will be described through
the model-based analysis of this primary outcome.
An intent-to-treat analytic approach will be used for
both the permutation test and for the model-based ana-
lyses, in that any cluster assigned to the intervention will
be considered treated, whether or not the ACT interven-
tion was delivered in that cluster. Also, both analyses will
use country as a blocking or stratification variable in the
analysis to reflect the randomization scheme.
To facilitate the model-based primary analysis, a detailed
analysis of baseline variables of the two groups (interven-
tion and control clusters) will be performed to assess the
extent, if any, of baseline imbalances between the two
groups of clusters. If baseline differences between the treat-
ment arms are identified, the covariables representing the
imbalanced variables will be used for adjusted analyses.
Imbalances at the cluster level (e.g., proportion of hospital
births, type of birth attendant) can be adjusted in the
model-based analysis. Because the primary interest is in
the decrease in the marginal neonatal mortality rate at the
cluster level, the generalized estimating equations (GEE)
method of Liang and Zeger [21] as implemented throughPRIMARY
- Neonatal mortality at 28 days
SECONDARY
- Rate of antenatal corticosteroid use
- Maternal infection from birth up to 7 and 42 days postpartum
- Perinatal mortality rate (stillbirths≥ 20 weeks GA or≥ 500 g+ neonatal
deaths before 7 days)
- Early neonatal mortality rate at 7 days after birth
- Mean neonatal weight at 7 and 28 days
- Neonatal and perinatal mortality rates by country
- Neonatal and perinatal mortality rates by type of setting (health facility
based deliveries vs. community based deliveries)
- Infant mortality rate at 42 days after birth.
- Early neonatal mortality (7 days after birth)
- Neonatal mortality at 28 days after birth
- Maternal infection from birth up to 7 days postpartum
- Maternal infection from birth up to 42 days postpartum
- Infant mortality rate at 42 days after birth
- Number of women receiving corticosteroids and number of doses
- Number of referrals
- Number of health providers trained
- Number of kits distributed
- Health providers’ opinions about the kits
- Number of kits fully used (all doses administered) at site
- Number of kits partially used (1–3 doses of dexamethasone) at site
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analysis. The model will control for cluster-level effects by
assuming country-specific correlation within clusters, and
all inferences will be based on the empirical correlation
matrix proposed by Liang and Zeger [21]. Additional
details of the model will be specified in the Statistical Ana-
lysis Plan.
In addition to the permutation tests and GEE models
described above, which focus on marginal risk in the
population, we will evaluate the effect of the outcome on
subject level risk by modeling the binary outcome using
generalized linear mixed models as implemented through
the SAS procedure GLIMMIX. In this procedure, cluster
will be treated as a random effect, with the cluster-
specific risk nested within intervention assumed to have
a Gaussian distribution. Again, both the GEE model and
the generalized linear mixed model will examine the
effects of potential confounders on mortality risk and the
heterogeneity of treatment effects across country.Secondary analyses—antenatal corticosteroid use
Although the primary study outcome is neonatal mortality,
a key secondary outcome is rate of antenatal corticosteroid
use. The analytic approach for this outcome will be com-
parable with that described for the primary outcome in
that both permutation and model-based analyses will be
implemented.
The primary results likely will need to be substantiated
with a sensitivity analysis of the results to missing out-
come data. The need for a detailed sensitivity analysis will
depend on the amount of missing data and any
intervention-dependent pattern to the missing data. A first
step will be to look for patterns by comparing observed
characteristics of participants who have missing data with
those having complete data. Then, if appropriate, both
nonparametric and parametric approaches will be under-
taken to evaluate the impact of missing data. Additional
details will be provided in the Statistical Analysis Plan.Other secondary outcome measures
The trial will also examine a number of additional clinical
and process measures as secondary outcomes. For each of
these outcome measures, descriptive statistics will be
computed as described in the introductory paragraphs
above. Model-based analyses will then be used to examine
the effects of the intervention on each of clinical and
process measures. For the clinical measures, GEE models
will be used to evaluate the effect of the intervention on
marginal risk of the outcome, with results reported for
both unadjusted analyses and analyses controlling for
covariates that differ across clusters. Also, generalized
linear mixed models will be used to examine the ef-




We expect to increase corticosteroids use from less
than 10% to at least 50% among preterm births. From
the estimates in the systematic review on the effect of
corticosteroids on mortality [4], we expect an asso-
ciated relative rate reduction in neonatal mortality of
25%–30%. The estimated effect size is lower than the
effect observed in the systematic review of clinical
trials [4], to take into consideration that we will use
birth weight as a proxy for GA and therefore will in-
clude a proportion of term small for GA babies who
may not benefit from receiving corticosteroids.
Intracluster Correlation Coefficient (ICC)
Using the MNH registry baseline data, the ICC is esti-
mated to be between 0.01 and 0.05. The estimate was
computed using data from 106 MNH registry clusters.
Power estimates
This trial will be conducted using all of the clusters from
the MNH registry determined to have the local infra-
structure to implement the protocol. On the basis of
preliminary information from the site investigators, we
anticipate between 90 and 100 clusters with at least 250
annual deliveries (average of 400) to be available for the
trial. Assuming that between 8% and 9% of deliveries are
premature, we anticipate a mean cluster size of between
50 and 75 premature newborns for an 18- to 24-month
trial. For 28-day neonatal mortality, a study size of 90
clusters with at least 60 LBW deliveries per cluster will
have a power of slightly more than 80% (Type I error
rate of 0.05) to detect a decrease of 30% in neonatal
mortality from 13% to 9%. For the outcome of antenatal
corticosteroid use among LBW infants, a sample size of
90 clusters with 50 events per cluster has a power of
greater than 0.99 to see an increase in utilization from a
start-rate of 10%–20% or more.
Ethical aspects
The use of antenatal corticosteroids for women at risk of
preterm birth is the standard of care in high-income coun-
tries as well as at the hospital level for most of the countries
participating in the trial. However, at each participating
site, the Institutional Review Board (IRB), Ministry of
Health, and physicians will be consulted on guidelines for
the use of antenatal corticosteroids to ensure that we are
in compliance with cultural, medical, and regulatory pol-
icies and norms. These drugs do not require regulatory
approval in the participating countries, nor do they require
approval from the Food and Drug Administration as an
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conducted outside the United States.
The protocol and the informed consent documents
were submitted and approved by the IRBs and ethics
committees of all participating clinical sites and Re-
search Triangle Institute (RTI), as the data center.
All participating communities must agree in advance
to participate in the study. Community-responsible
health authorities will provide their agreement to partici-
pate before beginning any activities and will act as
cluster ethical guardians. Community education, using
forums such as meetings and posters, will inform the
community and its authorities about the purpose and
procedures of the study. Communities will be informed
of their assignment to the control or intervention cluster
after randomization.
At the individual level, informed consent to collect data
and to administer corticosteroids will be requested. Because
high risk for preterm birth is frequently an emergency con-
dition (preterm labor, hemorrhage), to the extent possible,
informed consent to administer corticosteroids will be done
during pregnancy for all women enrolled in the MNH
registry. For those women eligible for corticosteroids ad-
ministration who were not asked for consent during preg-
nancy, consent would be sought with identification of the
risk of preterm delivery. In this case, women who present
at the community or health center level with signs or symp-
toms that make them eligible to receive corticosteroids, will
be consented only if they are in early labor (<6 cm of cer-
vical dilation or the local equivalent), or in a clinical condi-
tion not evaluated as an extreme emergency (like severe
hemorrhage, or imminent eclampsia).
At the hospital-level, where antenatal corticosteroids are
the standard of care for women having high risk of pre-
term birth, eligible women will not require consent.
All health providers working in the intervention clusters
that are eligible to be trained in the intervention proce-
dures will be invited to receive the training and asked for
their signed informed consent.
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